

## RESEARCH ARTICLE

## Open Access



# A comparison of the stem cell characteristics of murine tenocytes and tendon-derived stem cells

Katie Joanna Lee<sup>1\*</sup> , Peter David Clegg<sup>1,2,3</sup>, Eithne Josephine Comerford<sup>1,2</sup> and Elizabeth Gail Canty-Laird<sup>1,3</sup>

## Abstract

Tendon is a commonly injured soft musculoskeletal tissue, however, poor healing potential and ineffective treatment strategies result in persistent injuries and tissue that is unable to perform its normal physiological function. The identification of a stem cell population within tendon tissue holds therapeutic potential for treatment of tendon injuries. This study aimed, for the first time, to characterise and compare tenocyte and tendon-derived stem cell (TDSC) populations in murine tendon. Tenocytes and TDSCs were isolated from murine tail tendon. The cells were characterised for morphology, clonogenicity, proliferation, stem cell and tenogenic marker expression and multipotency. TDSCs demonstrated a rounded morphology, compared with a more fibroblastic morphology for tenocytes. Tenocytes had greater clonogenic potential and a smaller population doubling time compared with TDSCs. Stem cell and early tenogenic markers were more highly expressed in TDSCs, whereas late tenogenic markers were more highly expressed in tenocytes. Multipotency was increased in TDSCs with the presence of adipogenic differentiation which was absent in tenocytes. The differences in morphology, clonogenicity, stem cell marker expression and multipotency observed between tenocytes and TDSCs indicate that at least two cell populations are present in murine tail tendon. Determination of the most effective cell population for tendon repair is required in future studies, which in turn may aid in tendon repair strategies.

**Keywords:** Tendon, Tendon-derived stem cell, Tenocyte, Murine

## Background

Tendon is prone to injury and degeneration, and this is most often seen in occupational and sporting environments [1–3]. The healing process for tendon is poorly understood, however it is well documented that tendon tissue is unable to heal effectively resulting in painful and debilitating scar tissue, which is unable to perform its normal physiological function [1, 4]. The current treatment options for damaged or degenerated tendon vary depending on the severity and location of the tendinopathy [5–8] and include physiotherapy; pharmacotherapies, such as anti-inflammatories; corticosteroid injections; or surgery [5, 6, 9]. However, these treatment strategies are largely ineffective [5]; therefore, an alternative approach for the

management and treatment of tendinopathies is currently being sought.

Tenocytes are tendon-specific fibroblasts and traditionally were thought to be the only cell type present in tendon, however it is now thought that tenocytes account for approximately 95% of the cellular content of tendon, with progenitor cells, endothelial cells and chondrocytes comprising the remaining 5% [10]. Tenocytes are located between collagen fibrils and in the interfascicular matrix and they are responsible for the production of the ECM as well as the repair and maintenance of tendon tissue [10, 11]. The identification of a stem cell population within tendon tissue [12] holds therapeutic potential for treatment of tendon injuries. Tendon-derived stem cells (TDSCs) have been shown to be clonogenic, multipotent and express stem cell and tenogenic markers [12–15].

A number of tissue engineering strategies have utilised TDSCs for tendon repair with some successful outcomes

\* Correspondence: [leekj@liverpool.ac.uk](mailto:leekj@liverpool.ac.uk)

<sup>1</sup>Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK

Full list of author information is available at the end of the article



[16–20]. These studies highlight the potential use of TDSCs in tendon repair strategies, however further characterisation of TDSCs is necessary; particularly, the identification and characterisation of different cell populations within tendon tissue. Comparisons of tendon cell populations are lacking in the literature with only two studies comparing tenocytes and TDSC properties in the rabbit [14] and the horse [15]. These two studies reported conflicting results with large differences found between tenocyte and TDSC populations in the rabbit [14], but few differences observed in the horse [15]. No studies, to date, have compared tendon cell populations in rodents, despite the plethora of research on TDSCs in rats and mice.

This study aimed to isolate, characterise and compare tenocytes and TDSCs from murine tail tendon. We hypothesised that tenocytes would demonstrate phenotypic differences when compared with TDSCs, particularly differences in stem cell properties.

## Methods

### Isolation of murine tenocytes and TDSCs

HuR floxed embryos were obtained from Dimitris Kontoyiannis, Alexander Fleming Research Centre, Greece [21] and crossed with Aggrecan A1 Cre mice obtained from George Bou-Gharios, University of Liverpool, UK [22]. Tendon tissue was extracted from the tails of 6–8 week old C57BL/6 mice (HuR<sup>fl/fl</sup>Acan-Cre<sup>+/-</sup>) which were euthanased for reasons unrelated to this study, and digested for 3 h at 37 °C in 20 ml 375 U/ml collagenase type I and 0.05% trypsin. The resulting cell suspension was strained and then centrifuged at 1200 g for 10 min and the supernatant discarded. The cells were resuspended in complete DMEM (DMEM supplemented with 20% foetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 µg/ml amphotericin B) and counted using a haemocytometer. For tenocyte isolation the cells were seeded at  $1 \times 10^5$  cells in T25 culture flasks ( $4 \times 10^3$  cells/cm<sup>2</sup>) [23, 24] and for TDSC isolation the cells were seeded at 100 cells per well of a 6-well plate (10 cells/cm<sup>2</sup>) [13, 15, 16, 25–28]. All cells were cultured in complete DMEM at 37 °C, 5% CO<sub>2</sub> and 21% O<sub>2</sub>. TDSCs were cultured for 6–8 days before passaging, whereas tenocytes were cultured for 2–3 days, cells were split 2:1 for subsequent passages. For TDSCs colonies were isolated using cloning cylinders and local application of 0.05% trypsin. All cells were analysed at passage 2–3 [15].

### Cell proliferation assay

Cells at passage 2 were seeded at 10,000 cells in T25 culture flasks at day 0. At 80% confluency the cells were counted and the doubling time calculated using the formula below:

$$(\text{LOG}_{10}(\text{cell number after proliferation}) - \text{LOG}_{10}(\text{initial seeding density})) / \text{LOG}_{10}(2) \quad [29].$$

### Colony formation assay

Cells at passage 2 were seeded at 100 cells/cm<sup>2</sup> in 6-well cell culture plates. After 7 days in culture the cells were washed and then fixed with 6% glutaraldehyde and stained with 0.5% crystal violet solution [30]. The cells were washed again and imaged using a biomolecular imager (Typhoon FLA 7000, GE Healthcare) and analysed using ImageQuant software (GE Healthcare) for colony number and size.

### Tri-lineage differentiation assays

Cell monolayers were cultured for 21 days in osteogenic (complete DMEM containing 100 nM dexamethasone, 10 mM β-glycerophosphate and 50 mM ascorbic acid) [31] and adipogenic (complete DMEM containing 1 µM dexamethasone, 100 µM indomethacin, 10 µg/ml insulin and 500 µM IBMX) [32] induction media. Cell pellets (containing  $5 \times 10^5$  cells) were cultured for 21 days in chondrogenic (complete DMEM containing 100 nM dexamethasone, 25 µg/ml ascorbic acid, 10 ng/ml TGF-β3 and ITS+3 supplement) [33] induction media. Control cells for all treatments were cultured in complete DMEM. After culturing, the cells were stained with alizarin red and alkaline phosphatase to assess osteogenic differentiation, Oil Red O to assess adipogenic differentiation, or alcian blue for chondrogenic differentiation, as described in the PromoCell MSC application notes (<http://www.promocell.com/downloads/application-notes/>). Chondrogenic pellets were also paraffin embedded and 4 µm sections taken which were rehydrated and further stained with 1% Alcian blue solution and 0.1% Safranin O solution. In addition, separate cell pellets were digested in 10 U/ml papain solution for 3 h at 60 °C before the total sulphated glycosaminoglycan (sGAG) content was quantified. Dimethylmethylene blue dye was added to each sample and the absorbance read immediately at 570 nm. The sGAG content was calculated from a standard curve produced using chondroitin sulphate standards [34]. RNA was extracted from all assays to analyse lineage-specific gene expression.

### RNA extraction and quantitative real time-polymerase chain reaction (qRT-PCR)

RNA was extracted from all cell types by firstly applying Trizol to cell monolayers and using a cell scraper for cell detachment. After vortexing and centrifugation, 50 µg/ml glycoblue and 100% isopropanol were added to the aqueous phase for RNA precipitation. After centrifugation, the pellets were washed in 75% ethanol and resuspended in Tris-EDTA buffer. The quantity and quality of

RNA was assessed using a NanoDrop spectrophotometer (Thermo Fisher). 4 U DNase was then added to the samples to remove DNA, after which time an equal volume of phenol:chloroform:IAA was added to each sample. The RNA was then precipitated, centrifuged, washed in ethanol and the RNA quality assessed. cDNA was synthesised in a 25 µl reaction from 1 to 2 µg of total RNA. The conditions for cDNA synthesis were: incubation at 5 min at 70 °C, 60 min at 37 °C and 5 min at 93 °C with M-MLV reverse transcriptase and random-hexamer oligonucleotides (Promega) [35, 36].

qRT-PCR was conducted using a GoTaq(R) qPCR Master Mix (Promega), and in a 25 µl reaction 10 ng of cDNA was amplified in an AB 7300 Real Time PCR System (Applied Biosystems). After an initial denaturation for 10 min at 95 °C, 40 PCR cycles were performed consisting of 15 s at 95 °C and 1 min at 60 °C. Relative gene expression was calculated according to the comparative  $C_t$  method [35–37]. Murine specific primers were used (Table 1) and GAPDH was used as an internal control. Primers were designed using Primer-BLAST (NCBI), and the quality of each primer was tested using NetPrimer (Premier Biosoft). In addition, each primer was subjected to a BLAST (NCBI) search to ensure specificity. The best housekeeping gene was determined using the

geNorm algorithm [38] and all primers were tested for efficiency; efficiencies between 90 and 110% were deemed to be acceptable.

### Statistical analysis

Statistical analysis was performed using SPSS (IBM) and SigmaPlot (Systat Software Inc). To ensure data was normally distributed Shapiro Wilk tests were performed. For normally distributed data parametric tests were used for pairwise comparisons. For data which was not normally distributed  $\log_{10}$  data transformations were performed resulting in normally distributed data. For pairwise comparisons paired or independent Student's t-tests were used.  $P$ -values  $\leq 0.05$  were taken to be significant.

## Results


### Tenocyte and TDSC morphology and colony formation

Tenocytes and TDSCs demonstrated varying cell morphologies; tenocytes were large, flat and fibroblastic, whereas TDSCs were smaller and more rounded (Fig. 1a).

Both cell types were able to form colonies, however these colonies were not homogeneous. Tenocytes generally formed large sparse colonies, whereas TDSCs formed more compact, dense colonies. When quantified

**Table 1** Primer sequences for murine genes

Gene	Forward Primer	Reverse Primer
GAPDH	GAGAGGCCCTATCCCAACTC	GTGGGTGCAGCGAACTTTAT
CD90	GGATGAGGGCGACTACTTTTGT	TTGAGGCTCATGGGATTTCG
CD73	TGGTTCACCGTTTACAAAGG	CGCTCAGAATTGGAATTTAAC
TNC	AGGCGATCCAGCCAGTCAGT	ATGGACGGGGCACCTCCTGTC
SCX	AAGTTGAGCAAAGACCGTGACA	TGTGGACCCTCCTCTCTAAC
MKX	AGTAAAGACAGTCAAGCTGCCACTG	TCCTGGCCACTCTAGAAGCG
Sca-1	GTTTGCTGATTCTTCTGTGGCCC	ACTGCTGCCTCCTGAGTAACAC
NANOG	AGGGTCTGCTACTGAGATGCTCTG	CAACCACTGGTTTTCTGCCACCG
TNMD	AACTCCACCTCAGCAGTAGTCC	TTTCTTGGATACCTCGGGCCAGAA
THBS4	TCCTCCGCTACCTGAAGAATGATGG	TTCAATGGACTCTGGTTCTGGGTG
CD45	AGTTAGTGAATGGAGACCAGGAA	TCCATAAGTCTGCTTCCCTTCG
RUNX2	ATGCGTATTCTGTAGATCCG	TTGGGGAGGATTTGTGAAGAC
OC	CTCTGTCTCTGACCTCACA	CAGTCTCTAAA AGTGATAAC
OSX	GAAAGGAGGCACAAAGAAG	CACCAAGGAGTAGGTGTGTT
OPN	CATGAGATTGGCAGTATTTCG	TGCAGGCTGTAAGACTTCTCCT
FABP4	GAAGCTTGTCTCCAGTCAAAA	AGTCACGCCTTTCATAACACAT
PPAR $\gamma$	CTCCGTGATGGAAGACCACTC	AGACTCGGAACCTAATGGC
LEPTIN	CTTCACCCATTCTGAGITTTGT	TTCTCCAGGTCATTGGCTATCT
SOX9	TGGCAGACCAGTACCCGCATCT	TCTTTCTGTGTGCACGCGC
COL2A1	GGTTTGGAGAGACCATGAAC	TGGGTTTCGCAATGGATTGTG
AGG	TTGCCAGGGGGAGTTGTATTC	GACAGTCTCACGCCAGGTTTG



tenocytes produced significantly more colonies than TDSCs (Fig. 1b), however colony size was similar between cell types (Fig. 1c).

#### Tenocyte and TDSC proliferation

Both tenocytes and TDSCs proliferated very slowly and demonstrated very long population doubling times (PDT) with a mean ( $\pm$  SD) of 354 ( $\pm$ 140) and 508 ( $\pm$ 49) hours respectively (Fig. 2).


#### Tenocyte and TDSC marker expression

The gene expression of stem cell and tenogenic markers was assessed by qRT-PCR (Fig. 3). The majority of stem cell (Nanog and CD73) and early tenogenic markers (scleraxis and Mohawk) were more highly expressed in TDSCs when compared with tenocytes, whereas markers found in developed tendon (tenascin C, thrombospondin-4 and tenomodulin) exhibited higher expression in tenocytes compared to TDSCs. Expression of Nanog, scleraxis and Mohawk was significantly increased in TDSCs compared with tenocytes. Tenomodulin expression was significantly increased in tenocytes compared with TDSCs. The stem cell markers Sca-1 and CD90 were similarly expressed in both cell types. The haematopoietic stem cell marker CD45 demonstrated low expression with significantly higher levels observed for tenocytes compared with TDSCs.


#### Tenocyte and TDSC tri-lineage differentiation capacity

The ability of tenocytes and TDSCs to differentiate into different cell lineages was analysed by staining, glycosaminoglycan (GAG) assays and qRT-PCR for gene expression analysis.

Both cell types demonstrated osteogenic differentiation as assessed by alkaline phosphatase levels and alizarin









red staining (Fig. 4). No adipogenic differentiation was observed for tenocytes, however oil red O staining was seen in differentiated TDSCs (Fig. 4). Tenocytes demonstrated some chondrogenic differentiation, with an increase in pellet size and intensity of safranin O staining in positive samples (chondrogenic induction media) compared with negative samples (control media). Due to low cell numbers, it was not possible to undertake chondrogenic differentiation assays on TDSCs (Fig. 4).

There was an increase in mean sGAG formation for tenocytes from 0.25 (±0.3) µg in negative samples to 0.5 (±0.54) µg in positive samples, however this was not significant. sGAG content was not analysed in TDSCs due to low cell numbers (Fig. 5).

Gene expression analysis of lineage specific genes showed a significant increase in the expression of osteogenic markers RUNX2 (runt-related transcription factor 2) and OPN (osteopontin) for TDSCs, however expression in tenocytes was similar between negative and positive samples (Fig. 6). There were small increases in all adipogenic





marker genes, such as LEPTIN, FABP4 (fatty acid binding protein 4) and PPAR $\gamma$  (peroxisome proliferator-activated receptor gamma), for tenocytes, and much larger significant increases for TDSCs in positive samples compared to negative samples (Fig. 6). Similarly, there was an increase in the majority of chondrogenic markers, such as AGG (aggrecan) and COL2 (collagen type II) in positive samples compared with negative samples for tenocytes although these were not significant. Chondrogenic markers were not analysed in TDSCs due to low cell numbers (Fig. 6).


## Discussion

In this study we have isolated a population of cells in murine tendon that possess some of the traditional hallmarks of a stem cell: the ability to form colonies, the expression of stem cell markers and multipotency [39]. These findings are consistent with the published literature on murine TDSCs [12, 40–42]. The only discrepancy is the extended population doubling time observed in this study compared with previous reports. This could be explained by variations in cell isolation procedures. In this study we selected a low cell seeding density based on previous work in our group [15] and other studies [13, 16, 25–28], however some previous studies have used higher seeding densities. Alternatively, these differences may be due to mouse strain variation as research on murine mesenchymal stem cells (MSCs) has noted considerable variation in stem cell properties, including proliferation, between different strains of mice [43]. In addition, phenotypic differences of MSCs have been observed within certain strains of mice [44], highlighting the biological variation in murine stem cell populations. The TDSCs isolated in this study also stopped expanding

at early passages which made certain assays impossible to perform due to low cell numbers. This may be due to stem cell quiescence, senescence or terminal differentiation and could indicate that these cells are not in fact stem cells but a progenitor cell population. For this reason we were unable to perform chondrogenic differentiation assays on TDSCs. We observed only moderate levels of chondrogenic differentiation for tenocytes which were low compared to reports in human tendon cells [45] and murine tendon tissue [46]. It is likely that the chondrogenic differentiation potential of TDSCs would be increased compared to tenocytes, as seen for osteogenic and adipogenic differentiation.

To our knowledge, no studies have compared the phenotype of murine tenocytes and TDSCs and we observed a number of phenotypic differences between these two cell populations. Tenocytes and TDSCs demonstrated different cell morphologies and colony forming ability as well as differences in the expression of certain stem cell markers, and some differences in multipotency. TDSCs generally conformed to the criteria of MSCs, as specified by the International Society for Cellular Therapy [39] (although chondrogenic potential could not be confirmed), whereas tenocytes did not due to a lack of adipogenic differentiation. The primary similarity between tenocytes and TDSCs was the expression of tenogenic markers such as tenascin C and thrombospondin 4, which was expected given that both cell populations were derived from tendon tissue. No studies have previously compared murine tenocytes and TDSCs, however such a comparison has been performed in other species [14, 15]. Our previous work demonstrated no discernible differences between tenocyte and TDSC populations in equine superficial digital flexor tendon, however a restricted differentiation potential was observed for equine TDSCs [15]. In contrast, a comparison of tenocytes and TDSCs in rabbit Achilles and patellar tendon demonstrated considerable differences in stemness between the two cell populations [14], which are more consistent with our study. The phenotypic differences observed in this study between tenocytes and TDSCs suggest that these cells are distinct populations with differing properties.

TDSCs have been used in a number of tissue engineering strategies to promote tendon healing with some encouraging results in human and animal models [16–20, 47, 48]. However, many of these studies do not state the exact TDSC isolation method used, or use varying cell seeding densities; in addition, many studies have not fully characterised the cells used for tendon repair. Therefore, it is possible that different tendon cell populations have been used across studies, which were not always defined as TDSCs. It is necessary to determine which tendon



**Fig. 6** Gene expression analysis of lineage specific markers for murine tenocytes and TDSCs. Values are shown on a logarithmic scale and normalised to GAPDH. Error bars shown represent SD. Pairwise comparisons were performed using paired Student’s t-tests after Log<sub>10</sub> transformation of data. <sup>a</sup>*p* = 0.021, <sup>b</sup>*p* = 0.02, <sup>c</sup>*p* = 0.021, <sup>d</sup>*p* = 0.021, <sup>e</sup>*p* = 0.021. Chondrogenic marker genes are not shown for TDSCs due to low cell numbers. *n* = 6 biological replicates

cell population is most effective for tendon repair. The increased stemness of murine TDSCs may promote tendon repair, however the poor proliferative potential of these cells is not conducive to tendon regeneration. Alternatively, murine tenocytes which demonstrated improved proliferative potential may provide a more suitable cell population for tendon regeneration. It is possible that the restricted differentiation potential of tenocytes may actually provide a therapeutic benefit during tendon healing by avoiding aberrant differentiation. Analysis of different tendon cell populations in human tendon has not yet been performed, however the presence of multiple tendon cell populations in several species [14, 15] would suggest the presence of more than one tendon cell

population in human tendon. A comparison of tendon cell populations in humans is warranted, as well as investigation of the therapeutic potential of different tendon cell populations in vivo, which may highlight alternative, more effective tendon cell populations for human tendon repair strategies.

**Conclusion**

In conclusion, we have isolated and characterised two distinct tendon cell populations from murine tail tendon with differential properties. These tendon cell populations may provide therapeutic benefit for tendon injury and determination of the most effective cell population for tendon regeneration strategies in both humans and animals requires further investigation.

## Abbreviations

AB: alcian blue; AGG: aggrecan; ALP: alkaline phosphatase; AR: alizarin red; CD: cluster of differentiation; cDNA: complementary deoxyribonucleic acid; COL2A1: collagen type II alpha 1; DMEM: Dulbecco's modified Eagle's medium; EDTA: ethylenediaminetetraacetic acid; FABP4: fatty acid binding protein 4; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; IBMX: 3-isobutyl-1-methylxanthine; ITS: insulin transferrin selenium; MSC: mesenchymal stem cell; MKX: mohawk; OC: osteocalcin; OPN: osteopontin; ORO: oil red O; OSX: osterix; PDT: population doubling time; PPAR $\gamma$ : peroxisome proliferator-activated receptor gamma; qRT-PCR: quantitative real time-polymerase chain reaction; RNA: ribonucleic acid; RUNX2: runt-related transcription factor 2; Sca-1: stem cell antigen 1; SCX: scleraxis; SD: standard deviation; sGAG: sulphated glycosaminoglycan; SO: safranin O; TDSC: tendon-derived stem cell; TGF $\beta$ : transforming growth factor  $\beta$ ; THBS4: thrombospondin 4; TNC: tenascin C; TNMD: tenomodulin

## Acknowledgements

The authors would like to thank Dr. Simon Tew and Ms. Kirsty Johnson from the University of Liverpool for donation of murine tissue.

## Funding

This project was funded by the Marjorie Forrest Bequest and by the Institute of Ageing and Chronic Disease at the University of Liverpool, UK. The funding source had no involvement in study design; collection, analysis and interpretation of data; in writing the report; or in the decision to submit the article for publication.

## Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

## Authors' contributions

KJL acquired, analysed and interpreted data. PDC, EJC and EGC-L designed the study. KJL drafted the paper. All authors critically revised the manuscript and read and approved the final submitted version.

## Ethics approval and consent to participate

This project used surplus Schedule 1 murine tissue generated under UK Home Office project licence 70/7288 with ethics approval by the University of Liverpool's Animal Welfare and Ethical Review Body. All animal work was conducted under relevant national and international guidelines: Animal (Scientific Procedures) Act 1986; EU Directive 2010/63/EU.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK. <sup>2</sup>School of Veterinary Science, Leahurst Campus, University of Liverpool, Chester High Road, Neston CH64 7TE, UK. <sup>3</sup>The MRC-Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA), Liverpool, UK.

Received: 1 December 2017 Accepted: 4 April 2018

Published online: 12 April 2018

## References

- Maffulli N, Wong J, Almekinders LC. Types and epidemiology of tendinopathy. *Clinical Sports Medicine*. 2003;22:675–92.
- Kujala UM, Sarna S, Kapprio J. Cumulative incidence of Achilles tendon rupture and tendinopathy in male former elite athletes. *Clin J Sport Med*. 2005;15:133–5.
- O'Neil BA, Forsythe ME, Stanish WD. Chronic occupational repetitive strain injury. *Can Fam Physician*. 2001;47:311–6.
- Sharma P, Maffulli N. Biology of tendon injury: healing, modeling and remodeling. *J Musculoskelet Neuronal Interact*. 2006;6:181–90.
- Mayor RB. Treatment of athletic tendonopathy. *Conn Med*. 2012;76:471–5.
- Schwartz A, Watson JN, Hutchinson MR. Patellar tendinopathy. *Sports Health*. 2015;7:415–20.
- Lempainen L, Johansson K, Banke IJ, Ranne J, Mäkelä K, Sarimo J, Niemi P, Orava S. Expert opinion: diagnosis and treatment of proximal hamstring tendinopathy. *Muscles, Ligaments and Tendons Journal*. 2015;5:23–8.
- Goldin M, Malanga GA. Tendinopathy: a review of the pathophysiology and evidence for treatment. *Phys Sportsmed*. 2013;41:36–49.
- Coleman BD, Khan KM, Maffulli N, Cook JL, Wark JD. Studies of surgical outcome after patellar tendinopathy: clinical significance of methodological deficiencies and guidelines for future studies. *Scand J Med Sci Sports*. 2000;10:2–11.
- Franchi M, Trire A, Quaranta M, Orsini E, Ottani V. Collagen structure of tendon relates to function. *TheScientificWorldJOURNAL*. 2007;7:404–20.
- Kannus P. Structure of the tendon connective tissue. *Scand J Med Sci Sports*. 2000;10:312–20.
- Bi Y, Ehrirchiou D, Kilts TM, Inkson CA, Embree MC, Sonoyama W, Li L, Leet AI, Seo BM, Zhang L, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. *Nat Med*. 2007;13:1219–27.
- Rui YF, Lui PP, Li G, Fu SC, Lee YW, Chan KM. Isolation and characterization of multipotent rat tendon-derived stem cells. *Tissue Eng Part A*. 2010;16:1549–58.
- Zhang J, Wang JH. Characterization of differential properties of rabbit tendon stem cells and tenocytes. *BMC Musculoskelet Disord*. 2010;11:10.
- Williamson KA, Lee KJ, Humphreys WJE, Comerford EJV, Clegg PD, Canty-Laird EG. Restricted differentiation potential of progenitor cell populations obtained from the equine superficial digital flexor tendon (SDFT). *J Orthop Res*. 2015;33:849–58.
- Ni M, Lui P, Rui YF, Lee YW, Tan Q, Wong YM, Kong SK, Lau PM, Li G, Chan KM. Tendon-derived stem cells (TDSCs) promote tendon repair in a rat patellar tendon window defect model. *J Orthop Res*. 2012;30:613–9.
- Ni M, Rui YF, Tan Q, Liu Y, Xu LL, Chan KM, Wang Y, Li G. Engineered scaffold-free tendon tissue produced by tendon-derived stem cells. *Biomaterials*. 2013;34:2024–37.
- Zhang J, Li B, Wang JH. The role of engineered tendon matrix in the stemness of tendon stem cells in vitro and the promotion of tendon-like tissue formation in vivo. *Biomaterials*. 2011;32:6972–81.
- Jiang D, Xu B, Yang M, Zhao Z, Zhang Y, Li Z. Efficacy of tendon stem cells in fibroblast-derived matrix for tendon tissue engineering. *Cytherapy*. 2013;16:662–73.
- Yin Z, Chen X, Chen JL, Shen WL, Hieu Nguyen TM, Gao L, Ouyang HW. The regulation of tendon stem cell differentiation by the alignment of nanofibers. *Biomaterials*. 2010;31:2163–75.
- Katsanou V, Milatos S, Yiakouvakis A, Sgantzi N, Kotsoni A, Alexiou M, Harokopos V, Aidinis V, Hemberger M, Kontoyiannis DL. The RNA-binding protein Elavl1/HuR is essential for placental branching morphogenesis and embryonic development. *Mol Cell Biol*. 2009;29:2762–76.
- Cascio LL, Liu K, Nakamura H, Chu G, Lim NH, Chanalaris A, Saklatvala J, Nagase H, Bou-Gharios G. Generation of a mouse line harboring a bi-transgene expressing luciferase and tamoxifen-activatable creERT2 recombinase in cartilage. *Genesis*. 2014;52:110–9.
- Güngörmüş C, Kolankaya D. Characterization of type I, III and V collagens in high-density cultured tenocytes by triple-immunofluorescence technique. *Cytotechnology*. 2008;58:145–52.
- Schulze-Tanzil G, Mobasheri A, Clegg PD, Sendzik J, John T, Shakibaei M. Cultivation of human tenocytes in high-density culture. *Histochem Cell Biol*. 2004;122:219–28.
- Cheng B, Ge H, Zhou J, Zhang Q. TSG-6 mediates the effect of tendon derived stem cells for rotator cuff healing. *European Rev for Medical and Pharmacol Sci*. 2014;18:247–51.
- Lee WY, Lui PP, Rui YF. Hypoxia-mediated efficient expansion of human tendon-derived stem cells in vitro. *Tissue Eng Part A*. 2012;18:484–98.
- Mienaltowski M, Adams S, Birk D. Tendon proper- and peritendon-derived progenitor cells have unique tenogenic properties. *Stem Cell Research and Therapy*. 2014;5:86.



28. Tsai RYL, McKay RDG. Cell contact regulates fate choice by cortical stem cells. *J Neurosci*. 2000;20:3725–35.
29. Nagura I, Kokubu T, Mifune Y, Inui A, Takase F, Ueda Y, Kataoka T, Kurosaka M. Characterization of progenitor cells derived from torn human rotator cuff tendons by gene expression patterns of chondrogenesis, osteogenesis, and adipogenesis. *J Orthop Surg Res*. 2016;11:40.
30. Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. *Nat Protocols*. 2006;1:2315–9.
31. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. *J Cell Biochem*. 1997;64:295–312.
32. Cheng MT, Yang HW, Chen TH, Lee OKS. Isolation and characterization of multipotent stem cells from human cruciate ligaments. *Cell Prolif*. 2009;42:448–60.
33. Murdoch AD, Grady LM, Ablett MP, Katopodi T, Meadows RS, Hardingham TE. Chondrogenic differentiation of human bone marrow stem cells in Transwell cultures: generation of scaffold-free cartilage. *Stem Cells*. 2007;25:2786–96.
34. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. *Biochim Biophys Acta Gen Subj*. 1986;883:173–7.
35. McDermott BT, Ellis S, Bou-Gharios G, Clegg PD, Tew SR. RNA binding proteins regulate anabolic and catabolic gene expression in chondrocytes. *Osteoarthritis Cartil*. 2016;24:1263–73.
36. Reynolds JA, Haque S, Williamson K, Ray DW, Alexander MY, Bruce IN. Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. *Sci Rep*. 2016;6:22341.
37. Peffers MJ, Fang Y, Cheung K, Wei TKJ, Clegg PD, Birch HL. Transcriptome analysis of ageing in uninjured human Achilles tendon. *Arthritis Research & Therapy*. 2015;17:33.
38. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biology*. 2002;3:research0034.0031–11.
39. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8:315–7.
40. Alberton P, Dex S, Popov C, Shukunami C, Schieker M, Docheva D. Loss of Tenomodulin results in reduced self-renewal and augmented senescence of tendon stem/progenitor cells. *Stem Cells Dev*. 2014;24:597–609.
41. Mienaltowski MJ, Adams SM, Birk DE. Regional differences in stem cell/progenitor cell populations from the mouse achilles tendon. *Tissue Eng Part A*. 2013;19:199–210.
42. Zhang J, Wang JHC. The effects of mechanical loading on tendons - an in vivo and in vitro model study. *PLoS One*. 2013;8:e71740.
43. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. *Blood*. 2004;103:1662–8.
44. Lei J, Hui D, Huang W, Liao Y, Yang L, Liu L, Zhang Q, Qi G, Song W, Zhang Y, et al. Heterogeneity of the biological properties and gene expression profiles of murine bone marrow stromal cells. *Int J Biochem Cell Biol*. 2013;45:2431–43.
45. Stanco D, Viganò M, Perucca Orfei C, Di Giancamillo A, Thiebat G, Peretti G, de Girolamo L. In vitro characterization of stem/progenitor cells from semitendinosus and gracilis tendons as a possible new tool for cell-based therapy for tendon disorders. *Joints*. 2014;2:159–68.
46. Mikic B, Rossmeyer K, Bierwert L. Sexual dimorphism in the effect of GDF6 deficiency on murine tendon. *Journal of orthopaedic research : official publ of the Orthopaedic Res Soc*. 2009;27:1603–11.
47. Lui PPY, Wong OT, Lee YW. Transplantation of tendon-derived stem cells pre-treated with connective tissue growth factor and ascorbic acid in vitro promoted better tendon repair in a patellar tendon window injury rat model. *Cytotherapy*. 2016;18:99–112.
48. Chen L, Liu JP, Tang KL, Wang Q, Wang GD, Cai XH, Liu XM. Tendon derived stem cells promote platelet-rich plasma healing in collagenase-induced rat Achilles tendinopathy. *Cell Physiol Biochem*. 2014;34:2153–68.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

